• Haemonetics Corporation recently received U.S. Food and Drug Administration 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS technology, supported by a large multicenter trial of over 30,000 plasma donations showing improved average plasma volume per donation while maintaining safety.
• This next-generation, donor-tailored collection technology could enhance plasma center efficiency and reinforce Haemonetics’ position in high-value plasma collection workflows.
• We’ll now examine how FDA clearance for Persona PLUS, with its higher average plasma volume per donation, may influence Haemonetics’ investment narrative.

Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

Haemonetics Investment Narrative Recap

To own Haemonetics, you need to believe its core plasma and hospital technologies can justify concentration in a few U.S.-heavy franchises, while earnings quality and margins hold up despite competition. FDA clearance for NexSys PCS with Persona PLUS supports the view that plasma innovation remains a near-term catalyst, but it does not remove key risks around product concentration, possible volume swings in plasma collection, or pressure in vascular closure and interventional technologies.

The most relevant recent announcement alongside Persona PLUS is Haemonetics’ February 5, 2026 earnings update, which showed modest year-to-date revenue declines but higher profitability and set 2026 revenue guidance at US$1,215 million to US$1,255 million. Against that backdrop, Persona PLUS adds another data point in favor of technology-driven plasma efficiency as a potential support for the guidance range, though execution around VASCADE and the U.S.-centric revenue base remains crucial.

Yet this sits against the risk that rising competition and Haemonetics’ reliance on three U.S.-centric products could still unsettle revenue and margins in ways investors should be aware of...

Haemonetics' narrative projects $1.5 billion revenue and $257.9 million earnings by 2028. This requires 2.6% yearly revenue growth and about a $94.6 million earnings increase from $163.3 million today.

Uncover how Haemonetics' forecasts yield a $88.00 fair value, a 43% upside to its current price.

Exploring Other Perspectives

More optimistic analysts were already modeling Haemonetics reaching about US$1.6 billion in revenue and roughly US$296.8 million in earnings by 2028, so you should weigh how Persona PLUS and the concentration risk in its core U.S. products might either support or challenge those higher expectations, and consider how your own view could differ meaningfully from theirs.

Explore 2 other fair value estimates on Haemonetics - why the stock might be worth as much as 52% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Haemonetics research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Haemonetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Haemonetics' overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.